Propofol and Magnesium Sulfate Intravenous Infusion During Endoscopic Sinus Surgery
NCT ID: NCT04078659
Last Updated: 2019-09-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
50 participants
INTERVENTIONAL
2019-09-30
2020-02-29
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Propofol has been reported as a good agent for controlled hypotension by decreasing systemic vascular resistance secondary to arterial and venous vasodilation and a decrease in myocardial contractility with a dose-dependent property.
Magnesium Sulfate also has been reported as an agent of hypotensive anaesthesia by inhibition of the release of norepinephrine by blocking N-type calcium channel at the nerve ending beside acting as a vasodilator.
The well known pharmacodynamic effects of the intravenous infusion of propofol or Magnesium Sulfate may prove the advantage of this group in controlling intraoperative blood pressure thus reducing surgical field bleeding.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison Between Two Drugs (Propofol and Nitroglycerin as a Hypotensive Agents During Endoscopic Sinus Surgery
NCT04220281
Does Administration of Etomidate and Propofol of the Anesthetic Induction of Elderly Hypertensive Patient Provide Superior Blood Pressure Stability in Response to Direct Laryngoscopy When Compared to Propofol or Etomidate Alone?
NCT01248234
Anesthesia Techniques, Neuroprotection and Surgical Field in FESS Under Controlled Hypotension
NCT07181564
Preoperative Ephedrine Attenuates the Hemodynamic Responses of Propofol During Valve Surgery: A Dose Dependent Study
NCT01006863
Regional Block of the Nose for Hypotensive Anaesthesia in Septo-rhinoplasty
NCT03774693
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Propofol infusion
Patients received intravenous Propofol infusion
Propofol infusion
Following induction of anaesthesia, propofol infusion will be started 75 mcg/kg/min for the first 10-15 minutes, then a maintenance infusion of propofol (50 mcg/kg /min)
Lidocaine
Patients will receive iv lidocaine 1.5 mg/kg before induction of anaesthesia
Fentanyl
Patients will receive fentanyl 1-2 mcg/kg before induction of anaesthesia
Propofol
Patients will receive propofol in a dose of 1-2 mg /kg
Atracurium
Patients will receive 0.6 mg /kg iv atracurium over 60 sec, to facilitate tracheal intubation
Mechanical Ventilation
Patients lungs will be ventilated using the volume controlled mechanically ventilated with 40% oxygen in the air with positive end-expiratory pressure (PEEP) of 5 cmH2O, tidal volume 500 ml and Respiratory Rate of 12 per minute
Magnesium Sulfate infusion
Patients received intravenous Magnesium Sulfate infusion
Magnesium Sulfate infusion
Before induction of anaesthesia, Magnesium Sulfate infusion will be started at 40 mg/kg in 100 ml saline over 10 minutes as the loading dose then Magnesium sulfate infusion 10-15 mg/kg/hr started immediately after induction of anaesthesia
Lidocaine
Patients will receive iv lidocaine 1.5 mg/kg before induction of anaesthesia
Fentanyl
Patients will receive fentanyl 1-2 mcg/kg before induction of anaesthesia
Propofol
Patients will receive propofol in a dose of 1-2 mg /kg
Atracurium
Patients will receive 0.6 mg /kg iv atracurium over 60 sec, to facilitate tracheal intubation
Mechanical Ventilation
Patients lungs will be ventilated using the volume controlled mechanically ventilated with 40% oxygen in the air with positive end-expiratory pressure (PEEP) of 5 cmH2O, tidal volume 500 ml and Respiratory Rate of 12 per minute
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Propofol infusion
Following induction of anaesthesia, propofol infusion will be started 75 mcg/kg/min for the first 10-15 minutes, then a maintenance infusion of propofol (50 mcg/kg /min)
Magnesium Sulfate infusion
Before induction of anaesthesia, Magnesium Sulfate infusion will be started at 40 mg/kg in 100 ml saline over 10 minutes as the loading dose then Magnesium sulfate infusion 10-15 mg/kg/hr started immediately after induction of anaesthesia
Lidocaine
Patients will receive iv lidocaine 1.5 mg/kg before induction of anaesthesia
Fentanyl
Patients will receive fentanyl 1-2 mcg/kg before induction of anaesthesia
Propofol
Patients will receive propofol in a dose of 1-2 mg /kg
Atracurium
Patients will receive 0.6 mg /kg iv atracurium over 60 sec, to facilitate tracheal intubation
Mechanical Ventilation
Patients lungs will be ventilated using the volume controlled mechanically ventilated with 40% oxygen in the air with positive end-expiratory pressure (PEEP) of 5 cmH2O, tidal volume 500 ml and Respiratory Rate of 12 per minute
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients with hypersensitivity for any drug used in the study including magnesium, propofol or isoflurane
* Patients receiving magnesium sulfate supplementation
* Patients receiving drugs known to have significant interaction.
* Patients with ischemic heart disease
* Patients with heart defects
* Patients with significant heart failure
* Patients with increased intracranial pressure.
* Patients with systemic hypertension
18 Years
45 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mansoura University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hazem E Moawed
Role: STUDY_DIRECTOR
Assistant Professor of Anesthesia and Surgical Intensive Care
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nabil A Abd El-Mageed
Al Mansurah, DK, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS ∕18.08.247
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.